Health 2.0 Europe - The Leading Showcase of Online and Mobile Technologies in Healthcare

6-7 April 2010, Paris, France.
Health 2.0 Europe, known for its live demos, will assemble speakers from 12 European countries and the U.S., in order to explain the world of Web 2.0 (both computer and mobile) in health care with its patient and professional communities, online consultation, rating sites, personal health records, specialized search engines, prevention programs.

The Health 2.0 Europe Conference's panels and topics will include:

Search & content - How does the best of vertical search technology resonate in a world where government programs provide significant amounts of health content?

Demonstrations & case studies from:

  • Segolène Ayme, Orphanet
  • Frankie Dolan, MedWorm
  • Célia Boyer, Health On the Net Foundation
  • West Shell, Healthline Networks
  • Steven Krein, Organized Wisdom
  • Berci Mesko, Webicina

Patients and Online Communities - The advancement and popularity of patient communities online is an international phenomenon. We'll be examining communities in different cultures, languages and context, and see what impact they have on care delivery in different countries–and what the internationalization of information means for patients and doctors.

The patient perspective from:

  • Roberto Ascione, PagineMediche.it
  • Gilles Frydman, ACOR
  • Ben Heywood, PatientsLikeMe
  • Neil Bacon, iWantGreatCare
Research and Commentary from:
  • Alexander Schachinger, Humboldt University Berlin
  • Susannah Fox, Pew Internet

Physicians and Online Communities - In the US, physician social networks are in some aspects replacing the function of traditional physician professional organizations. Physician activity online has a long tradition in Europe too.

The physician perspective from:

  • Daniel Palestrant, Sermo america
  • Miguel Cabrer, Medting Spain

Health 2.0 tools - Consumer tools are an essential piece of the Health 2.0 landscape. Some of the most sophisticated drug, condition and treatment tools are giving patients as much if not more information than their physicians. Their use is already controversial in the US, but how is it playing out in different medical cultures across Europe?

  • Isabelle Adenot, French National Order of Pharmacists
  • Roy Schoenberg, American Well
  • David Doherty, 3G Doctor
  • Roni Zeiger, Google
  • Sabine Pinedo, stichting Begeleide Zelfzorg (sBZ)
  • Neil Williams, Microsoft
  • Mohammad Al-Ubaydli, Patients Know Best

Keynote Addresses: The government view point - How does Health 2.0 fit into the various national IT strategies for EMRs, PHRs and national health and wellness?

  • Etienne Caniard, French National Authority for Health France
  • Dutch Government Representative, Raad voor de Volksgezondheid en Zorg NL

Hospitals, Payers and Health 2.0 - A look at how hospitals and payers are interacting with doctors and patients in the world of Health 2.0.

Demonstrations & commentary from:

  • Paul Hodgkin, PatientOpinion UK
  • Don Kemper, Healthwise US
  • Jean-Pascal Del Bano, Le Guide Santé France

Pharma and Health 2.0 - How is Health 2.0 affecting Pharma? A look at how pharmaceutical companies are connecting with doctors and patients in new ways, and how Health 2.0 is changing the way they're conducting clinical research.

  • Len Starnes, Bayer Health
  • Sylvie St-Laurent, Pfizer
  • Daniel Ghinn, Creation Interactive
  • Sophie Kune, ParleAvecElles
  • René Hansen, UCB

For further information and registration, please visit:
http://www.health2con.com/paris2010/

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...